


Fluvoxamine Maleate

03/21

ALTERNATE NAMES: (Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate; (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime Maleate

CATALOG #: B3118-10 10 mg
B3118-50 50 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₉H₂₅F₃N₂O₆

MOLECULAR WEIGHT: 434.4

CAS NUMBER: 61718-82-9

APPEARANCE: White powder

PURITY: ≥ 98% (HPLC)

SOLUBILITY: ~30 mg/ml in DMSO
~25 mg/ml in Ethanol
~5 mg/ml in PBS (pH 7.2)

DESCRIPTION: Fluvoxamine is an inhibitor of 5-hydroxytryptamine (5-HT) re-uptake. It inhibits the uptake of 5-hydroxytryptamine in guinea-pig blood platelets with a pI₅₀ (the negative logarithm of the molar concentration causing 50 % inhibition) of 6.4. It also has a high affinity at the sigma-1 receptor. It is used as an antidepressant and preliminary studies have shown that fluvoxamine is beneficial in reducing clinical deterioration in COVID-19.

STORAGE TEMPERATURE: -20 °C. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE:

1. Claassen, V., Davies, J. E., Hertting, G. et al. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. *Br J Pharmacol.* 60(4):505-16 (1977).
2. Lenze, E.J., Mattar, C., Zorumski, C.F., et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial. *324(22):2292-2300 (2020).*

RELATED PRODUCTS:

(S)-Duloxetine hydrochloride (Cat. No. B2680)
 Venlafaxine hydrochloride (Cat. No. B2683)
 Pimavanserin Tartrate (Cat. No. B1915)
 LY-310762 hydrochloride (B2190)
 Sertraline (hydrochloride) (Cat. No. B2393)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*